Cargando…
Drug-induced immune-mediated thrombocytopenia secondary to sunitinib in a patient with metastatic renal cell carcinoma: a case report
INTRODUCTION: Sunitinib is an oral multi-targeted tyrosine kinase inhibitor approved for first line treatment for metastatic renal cell carcinoma and imatinib-resistant metastatic gastrointestinal stromal tumors. Sunitinib administration can cause myelosuppression resulting in neutropenia and thromb...
Autores principales: | Ansari, Zia, George, Mathew K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3599754/ https://www.ncbi.nlm.nih.gov/pubmed/23442444 http://dx.doi.org/10.1186/1752-1947-7-54 |
Ejemplares similares
-
Sunitinib Induced Immune Thrombocytopenia
por: Shekarriz, Ramin, et al.
Publicado: (2015) -
Secondary Immune Thrombocytopenia in Metastatic Renal Cell Carcinoma: A Case Report and Discussion of the Literature
por: Cockrell, Dillon C., et al.
Publicado: (2020) -
Drug-induced immune thrombocytopenic purpura secondary to sunitinib
por: Trinkaus, M., et al.
Publicado: (2008) -
Erythema multiforme major induced by sunitinib for metastatic renal cell carcinoma
por: Watanabe, Daisuke, et al.
Publicado: (2019) -
Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
por: Dougherty, Sean C., et al.
Publicado: (2021)